

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 8080

Title: Muscovite is protective against non-steroidal anti-inflammatory drug-induced small bowel injury

Reviewer code: 02441480

Science editor: Ma, Ya-Juan

Date sent for review: 2013-12-16 09:26

Date reviewed: 2013-12-23 13:54

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

This manuscript is very interesting in prevention of NSAIDs-induced small bowel injuries. This field has made not remarkable progress recently. But it is possible that Muscovite can be candidate drug for preventing NSAID-induced enteropathy. Some problems are listed bellows. 1. About Introduction. Have the relation of COX-2 inhibitor and cardiovascular event been established? please tell me. 2. About study design. Recently, PPI occurred intestinal mucosal injuries, for example microscopic enteropathy, especially omeprazol. please discuss the possibility of PPI-induced bowel injuries. 3. This small bowel injury categories are very clear and meaningful. please show me the basis of this classification, especially the number of ulcers 3. 4. Are the subjects appeared mucosal breaks at baseline really healthy? Don't they have the bowel disease, anything else? Do you need them exclude? 5. About Discussion. It seems that the reports of medicinal action of Muscovite are few. I want to know more Muscovite's information and knowledge. 6. This report should indicate the comparison of the prevention of conventional NSAIDs and COX-2 inhibitor. There are many report about the prevention of small bowel injuries with COX-2 inhibitor. Please discussion. And please indicate to The other prevention of small bowel injuries.

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 8080

Title: Muscovite is protective against non-steroidal anti-inflammatory drug-induced small bowel injury

Reviewer code: 00227406

Science editor: Ma, Ya-Juan

Date sent for review: 2013-12-16 09:26

Date reviewed: 2014-01-01 20:42

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
[Y] Grade A (Excellent)	[Y] Grade A: Priority Publishing	Google Search:	[Y] Accept
[] Grade B (Very good)	[] Grade B: minor language polishing	[] Existed	[] High priority for publication
[] Grade C (Good)	[] Grade C: a great deal of language polishing	[] No records	[] Rejection
[] Grade D (Fair)	[] Grade D: rejected	BPG Search:	[] Minor revision
[] Grade E (Poor)		[] Existed	[] Major revision
		[] No records	

COMMENTS TO AUTHORS

I would like to commend Huang and Lu et al on their study "Muscovite is protective against non-steroidal anti-inflammatory drug-induced small bowel injury". It is a very well designed and conducted study examining the potential protective effects of muscovite on the small bowel in those healthy volunteers taking NSAID for 2 weeks. I would certainly recommend publication of the paper as it adds significantly to the literature on NSAID enteropathy related to NSAID ingestion. The only comment I would make relates to the quality of the small bowel preparation prior to capsule endoscopy (CE). This is a major limitation in the quality of the examination in some patients (particularly in the West) and one wonders whether the preparation was excellent in all. Did any patients receive simethicone prior to the CE? Finally, it would be helpful if comparative images were displayed from individual subjects in each arm of the study. However, this is a well conducted study and I would recommend publication.

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 8080

Title: Muscovite is protective against non-steroidal anti-inflammatory drug-induced small bowel injury

Reviewer code: 02725329

Science editor: Ma, Ya-Juan

Date sent for review: 2013-12-16 09:26

Date reviewed: 2014-01-03 17:48

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

Comments to the Author: In this clinical trial, authors investigated the protective effect of muscovite to NSAID-induced small bowel injury. Thirty-two healthy volunteers were randomized to take either diclofenac (75mg twice daily) or muscovite (3g twice daily) in addition to diclofenac (75mg twice daily) for 14 days. The percentage of subjects with small intestinal mucosal breaks was greater in the NSAID control group (71%) than NSAID-muscovite group (31%) ($p=0.028$). Although this study was an open-label clinical trial, it indicated that muscovite would reduce NSAID-induced small bowel injury. Major points: 1. Abstract and Results. In this trial, the primary end point was the mean number of small intestinal mucosal per subject. However, this result of the end point was not indicated in Abstract, and not shown in the beginning of Result. 2. Patients and methods (Table 1). The authors should describe the definition of CE findings, such as petechiae, erosion, ulcer, and denuded area. 3. Results (Table 5). Lymphangiectasis would not be associated with the administration of NSAID. 4. Discussion. Why was the statistically significant difference in the distribution of small intestinal mucosal breaks seen only in the NSAID control group? The authors should describe this result in Discussion. Minor points: 1. Patients and methods. The authors should show the Clinical trial number.